Published in Epilepsia on January 05, 2012
Ezogabine (KCNQ2/3 channel opener) prevents delayed activation of meningeal nociceptors if given before but not after the occurrence of cortical spreading depression. Epilepsy Behav (2013) 1.40
Antiseizure drugs differentially modulate θ-burst induced long-term potentiation in C57BL/6 mice. Epilepsia (2014) 0.94
Antiepileptic drugs 2012: recent advances and trends. Mayo Clin Proc (2012) 0.93
One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders. Br J Pharmacol (2013) 0.92
Before epilepsy unfolds: opening up the potassium door in neonatal seizures. Nat Med (2012) 0.86
Potassium channels: a review of broadening therapeutic possibilities for neurological diseases. J Neurol (2012) 0.85
The anticonvulsant retigabine is a subtype selective modulator of GABAA receptors. Epilepsia (2015) 0.85
Current and emerging treatments for absence seizures in young patients. Neuropsychiatr Dis Treat (2013) 0.84
Ion channels as drug targets in central nervous system disorders. Curr Med Chem (2013) 0.84
Polarized axonal surface expression of neuronal KCNQ potassium channels is regulated by calmodulin interaction with KCNQ2 subunit. PLoS One (2014) 0.83
Retigabine, a Kv7.2/Kv7.3-Channel Opener, Attenuates Drug-Induced Seizures in Knock-In Mice Harboring Kcnq2 Mutations. PLoS One (2016) 0.81
Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy. Drug Healthc Patient Saf (2012) 0.80
Efficacy of retigabine in adjunctive treatment of partial onset seizures in adults. J Cent Nerv Syst Dis (2013) 0.77
Efficacy of Retigabine on Acute Limbic Seizures in Adult Rats. J Epilepsy Res (2015) 0.76
Protective role of Kv7 channels in oxygen and glucose deprivation-induced damage in rat caudate brain slices. J Cereb Blood Flow Metab (2015) 0.76
Age-dependent Electroencephalographic Differences in the Genetic Absence Epilepsy Rats from Strasbourg (GAERS) Model of Absence Epilepsy. Malays J Med Sci (2014) 0.75
Activation of KCNQ channels located on the skeletal muscle membrane by retigabine and its influence on the maximal muscle force in rat muscle strips. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov (2010) 2.22
Antiepileptic drug therapy: does mechanism of action matter? Epilepsy Behav (2011) 2.20
A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome. PLoS Genet (2009) 2.12
From the editors: Epilepsia's survey on the necessity of the Wada test and intracranial electrodes for cortical mapping. Epilepsia (2014) 2.02
Assessment and surgical outcomes for mild type I and severe type II cortical dysplasia: a critical review and the UCLA experience. Epilepsia (2009) 1.99
Childhood absence epilepsy: behavioral, cognitive, and linguistic comorbidities. Epilepsia (2008) 1.99
Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br J Pharmacol (2009) 1.94
Models for epilepsy and epileptogenesis: report from the NIH workshop, Bethesda, Maryland. Epilepsia (2002) 1.91
The voltage-gated sodium channel Na(v)1.9 is an effector of peripheral inflammatory pain hypersensitivity. J Neurosci (2006) 1.88
Acetoacetate, acetone, and dibenzylamine (a contaminant in l-(+)-beta-hydroxybutyrate) exhibit direct anticonvulsant actions in vivo. Epilepsia (2002) 1.82
Pharmacological plasticity of GABA(A) receptors at dentate gyrus synapses in a rat model of temporal lobe epilepsy. J Physiol (2004) 1.66
Progressive neurodegeneration in patients with primary immunodeficiency disease on IVIG treatment. Clin Immunol (2002) 1.64
TRPV channels as temperature sensors. Cell Calcium (2003) 1.63
Predictive value of cortical injury for the development of temporal lobe epilepsy in 21-day-old rats: an MRI approach using the lithium-pilocarpine model. Epilepsia (2002) 1.62
The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia (2012) 1.59
Varicella-zoster virus: an overlooked cause of aseptic meningitis. Pediatr Infect Dis J (2003) 1.52
Maternal immune activation promotes hippocampal kindling epileptogenesis in mice. Ann Neurol (2013) 1.49
Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia (2012) 1.45
Should consciousness describe seizures and what terms should be applied? Epilepsia's survey results. Epilepsia (2014) 1.42
Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia. Pediatr Neurol (2006) 1.42
Reduced anesthetization during the intracarotid amobarbital (Wada) test in patients taking carbonic anhydrase-inhibiting medications. Epilepsia (2005) 1.41
Developmental characteristics of picrotoxin-induced convulsions in rats with genetic absence epilepsy. Exp Neurol (2003) 1.41
Reasons for discrepancy between incidence and prevalence of epilepsy in lower income countries: Epilepsia's survey results. Epilepsia (2014) 1.38
Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res (2010) 1.35
Mouse models of human KCNQ2 and KCNQ3 mutations for benign familial neonatal convulsions show seizures and neuronal plasticity without synaptic reorganization. J Physiol (2008) 1.35
Effects of piperine, the pungent component of black pepper, at the human vanilloid receptor (TRPV1). Br J Pharmacol (2005) 1.33
Subclinical early posttraumatic seizures detected by continuous EEG monitoring in a consecutive pediatric cohort. Epilepsia (2013) 1.32
Seizures following picornavirus infection. Epilepsia (2008) 1.31
Systemic peripheral artery relaxation by KCNQ channel openers and hydrogen sulfide. J Hypertens (2010) 1.28
The ketogenic diet in a pill: is this possible? Epilepsia (2008) 1.28
Innate but not adaptive immune responses contribute to behavioral seizures following viral infection. Epilepsia (2009) 1.26
Comparative anticonvulsant efficacy in the corneal kindled mouse model of partial epilepsy: Correlation with other seizure and epilepsy models. Epilepsy Res (2010) 1.25
A spontaneous mutation involving Kcnq2 (Kv7.2) reduces M-current density and spike frequency adaptation in mouse CA1 neurons. J Neurosci (2006) 1.24
Treatment of experimental status epilepticus in immature rats: dissociation between anticonvulsant and antiepileptogenic effects. Pediatr Res (2006) 1.24
Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res (2012) 1.24
Discovery of antiepileptic drugs. Neurotherapeutics (2007) 1.24
Targeting gut T cell Ca2+ release-activated Ca2+ channels inhibits T cell cytokine production and T-box transcription factor T-bet in inflammatory bowel disease. J Immunol (2009) 1.22
Interleukin-6, produced by resident cells of the central nervous system and infiltrating cells, contributes to the development of seizures following viral infection. J Virol (2011) 1.22
Magnetic resonance imaging in the study of the lithium-pilocarpine model of temporal lobe epilepsy in adult rats. Epilepsia (2002) 1.21
Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res (2007) 1.20
Neuronal-glial interactions in rats fed a ketogenic diet. Neurochem Int (2006) 1.20
Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res (2008) 1.20
Regulation of kindling epileptogenesis by hippocampal galanin type 1 and type 2 receptors: The effects of subtype-selective agonists and the role of G-protein-mediated signaling. J Pharmacol Exp Ther (2006) 1.19
Psychopathology and pediatric complex partial seizures: seizure-related, cognitive, and linguistic variables. Epilepsia (2004) 1.19
Epilepsy biomarkers. Epilepsia (2013) 1.19
Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine. Brain (2008) 1.18
Spontaneous deletion of epilepsy gene orthologs in a mutant mouse with a low electroconvulsive threshold. Hum Mol Genet (2003) 1.17
Elevated plasma corticosterone level and depressive behavior in experimental temporal lobe epilepsy. Neurobiol Dis (2009) 1.16
Frontal and temporal volumes in Childhood Absence Epilepsy. Epilepsia (2009) 1.15
Development of postinfection epilepsy after Theiler's virus infection of C57BL/6 mice. J Neuropathol Exp Neurol (2010) 1.14
NIRS-measured oxy- and deoxyhemoglobin changes associated with EEG spike-and-wave discharges in children. Epilepsia (2008) 1.13
Models of pediatric epilepsies: strategies and opportunities. Epilepsia (2006) 1.12
Kindling epileptogenesis in immature rats leads to persistent depressive behavior. Epilepsy Behav (2007) 1.12
Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugs. Pharmacol Ther (2009) 1.10
A 5-month period of epilepsy impairs spatial memory, decreases anxiety, but spares object recognition in the lithium-pilocarpine model in adult rats. Epilepsia (2005) 1.10
Inflammation exacerbates seizure-induced injury in the immature brain. Epilepsia (2007) 1.09
Characterisation of 5-HT3C, 5-HT3D and 5-HT3E receptor subunits: evolution, distribution and function. J Neurochem (2008) 1.08
Vigabatrin, the GABA-transaminase inhibitor, damages cone photoreceptors in rats. Ann Neurol (2004) 1.08
Temporal patterns of the cerebral inflammatory response in the rat lithium-pilocarpine model of temporal lobe epilepsy. Neurobiol Dis (2004) 1.07
Paroxysmal fast activity: an interictal scalp EEG marker of epileptogenesis in children. Epilepsy Res (2008) 1.06
Conservation of functional and pharmacological properties in the distantly related temperature sensors TRVP1 and TRPM8. Mol Pharmacol (2005) 1.06
Language in pediatric epilepsy. Epilepsia (2009) 1.06
Postnatal hypoxic-ischemic brain injury alters mechanisms mediating neuronal glucose transport. Am J Physiol Regul Integr Comp Physiol (2003) 1.06
Depolarizing actions of GABA in immature neurons depend neither on ketone bodies nor on pyruvate. J Neurosci (2011) 1.05
Theiler's virus infection chronically alters seizure susceptibility. Epilepsia (2009) 1.05
Pathogenesis and pharmacology of epilepsy in the lithium-pilocarpine model. Epilepsia (2007) 1.03
Increased phasic activity of VTA dopamine neurons in mice 3 weeks after repeated social defeat. Behav Brain Res (2010) 1.03
Antiepileptogenic and antiictogenic effects of retigabine under conditions of rapid kindling: an ontogenic study. Epilepsia (2008) 1.02
Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities. J Med Chem (2008) 1.02
Neonatal seizures: after all these years we still love what doesn't work. Neurology (2005) 1.00
A robust statistics-based global energy function for the alignment of serially acquired autoradiographic sections. J Neurosci Methods (2003) 1.00
Finding a better drug for epilepsy: antiepileptogenesis targets. Epilepsia (2012) 0.99
Differential effects of the anticonvulsant topiramate on neurobehavioral and histological outcomes following traumatic brain injury in rats. J Neurotrauma (2004) 0.99
Effects of pan- and subtype-selective N-methyl-D-aspartate receptor antagonists on cortical spreading depression in the rat: therapeutic potential for migraine. J Pharmacol Exp Ther (2007) 0.99
An animal model of chronic inflammatory pain: pharmacological and temporal differentiation from acute models. Eur J Pain (2005) 0.99
Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. Epilepsy Behav (2004) 0.99
Inflammation induced by LPS enhances epileptogenesis in immature rat and may be partially reversed by IL1RA. Epilepsia (2010) 0.99
Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens. Am J Ophthalmol (2010) 0.99
Decreased expression of glutamate transporters in genetic absence epilepsy rats before seizure occurrence. J Neurochem (2002) 0.98
Children with ESES: variability in the syndrome. Epilepsy Res (2006) 0.98
Selective reorganization of GABAergic transmission in neonatal ventral hippocampal-lesioned rats. Int J Neuropsychopharmacol (2009) 0.98
Comorbidity between epilepsy and depression: experimental evidence for the involvement of serotonergic, glucocorticoid, and neuroinflammatory mechanisms. Epilepsia (2010) 0.98
Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett (2006) 0.98
Epileptogenesis after self-sustaining status epilepticus. Epilepsia (2002) 0.97
Bumetanide inhibits rapid kindling in neonatal rats. Epilepsia (2009) 0.97
Issues related to development of new antiseizure treatments. Epilepsia (2013) 0.96
Synaptic and extrasynaptic GABA transporters as targets for anti-epileptic drugs. J Neurochem (2009) 0.95
GABA transporters as drug targets for modulation of GABAergic activity. Biochem Pharmacol (2004) 0.95
Age-dependent effects of topiramate on the acquisition and the retention of rapid kindling. Epilepsia (2007) 0.95
Metabolism is normal in astrocytes in chronically epileptic rats: a (13)C NMR study of neuronal-glial interactions in a model of temporal lobe epilepsy. J Cereb Blood Flow Metab (2005) 0.95
High performance and bendable few-layered InSe photodetectors with broad spectral response. Nano Lett (2014) 0.95
Comorbidity between epilepsy and depression: role of hippocampal interleukin-1beta. Neurobiol Dis (2009) 0.94
Antiseizure drugs differentially modulate θ-burst induced long-term potentiation in C57BL/6 mice. Epilepsia (2014) 0.94
Conantokin-L, a new NMDA receptor antagonist: determinants for anticonvulsant potency. Epilepsy Res (2002) 0.94
Development of new treatment approaches for epilepsy: unmet needs and opportunities. Epilepsia (2013) 0.94
Role for complement in the development of seizures following acute viral infection. J Virol (2010) 0.94
Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem (2009) 0.94
Inflammation enhances epileptogenesis in the developing rat brain. Neurobiol Dis (2010) 0.93
Mice carrying the szt1 mutation exhibit increased seizure susceptibility and altered sensitivity to compounds acting at the m-channel. Epilepsia (2004) 0.93
Effects of carisbamate (RWJ-333369) in two models of genetically determined generalized epilepsy, the GAERS and the audiogenic Wistar AS. Epilepsia (2007) 0.92